ValuEngine lowered shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) from a hold rating to a sell rating in a research report sent to investors on Thursday.
Several other research analysts also recently commented on RETA. Zacks Investment Research upgraded Reata Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, October 24th. Robert W. Baird reiterated a buy rating and set a $47.00 target price on shares of Reata Pharmaceuticals in a research note on Tuesday, October 24th. Citigroup Inc. reiterated a buy rating and set a $78.00 target price (down from $87.00) on shares of Reata Pharmaceuticals in a research note on Wednesday, August 23rd. Stifel Nicolaus reiterated a buy rating and set a $50.00 target price (up from $38.00) on shares of Reata Pharmaceuticals in a research note on Tuesday, July 25th. Finally, Leerink Swann assumed coverage on Reata Pharmaceuticals in a research note on Wednesday, September 13th. They set an outperform rating and a $43.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $54.71.
Reata Pharmaceuticals (NASDAQ:RETA) opened at $27.56 on Thursday. The company has a current ratio of 1.34, a quick ratio of 1.34 and a debt-to-equity ratio of -0.09. Reata Pharmaceuticals has a one year low of $18.51 and a one year high of $41.60.
COPYRIGHT VIOLATION WARNING: This article was first posted by Transcript Daily and is owned by of Transcript Daily. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/11/13/reata-pharmaceuticals-inc-reta-lowered-to-sell-at-valuengine.html.
A number of large investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN lifted its holdings in Reata Pharmaceuticals by 532.7% during the 3rd quarter. Wells Fargo & Company MN now owns 35,372 shares of the company’s stock worth $1,099,000 after purchasing an additional 29,781 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $256,000. American International Group Inc. lifted its holdings in Reata Pharmaceuticals by 42.5% during the 3rd quarter. American International Group Inc. now owns 7,528 shares of the company’s stock worth $234,000 after purchasing an additional 2,247 shares during the last quarter. Sphera Funds Management LTD. acquired a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $6,376,000. Finally, Ameriprise Financial Inc. acquired a new stake in Reata Pharmaceuticals during the 3rd quarter worth approximately $997,000. 17.00% of the stock is owned by institutional investors and hedge funds.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.